NCT06413082View on ClinicalTrials.gov

Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

July 7, 2023

Study Completion Date

September 3, 2023

Conditions
HypertensionGenetic PredispositionDrug Effect
Interventions
DRUG

Torasemide

The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups

DRUG

Spironolactone

The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups

Trial Locations (2)

20132

San Raffaele Hospital, Milan

IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors
lead

Ospedale San Raffaele

OTHER

NCT06413082 - Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment | Biotech Hunter | Biotech Hunter